EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial

Yasuhiro Nishiyama iD, Kazumi Kimura iD, Toshiaki Otsuka, Kazunori Toyoda iD, Shinichiro Uchiyama iD, Haruhiko Hoshino iD, Nobuyuki Sakai iD, Yasushi Okada iD, Hideki Origasa iD, Hiroaki Naritomi iD, Kiyohiro Houkin, Keiji Yamaguchi iD und 8 weitere

Stroke · 2023-03 · 54 (3) · 697-705

DOI: 10.1161/strokeaha.122.039900 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2023-03. Verfasst von Yasuhiro Nishiyama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology (Y.N., K.K.), Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Stroke, Lacunar, Stroke. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effectiveness of long-term dual antiplatelet therapy (DAPT) to prevent recurrent strokes in patients with lacunar stroke remains unclarified. Therefore, this study aimed to compare and to elucidate the safety and effectiveness of DAPT and single antiplatelet therapy (SAPT) in preventing recurrence in chronic lacunar stroke.

Methods

CSPS.com (Cilostazol Stroke Prevention Study for Antiplatelet Combination) was a prospective, multicenter, randomized controlled trial. In this prespecified subanalysis, 925 patients (mean age, 69.5 years; 69.4% men) with lacunar stroke were selected from 1884 patients with high-risk noncardioembolic stroke, enrolled in the CSPS.com trial after 8 to 180 days following stroke. Patients were randomly assigned to receive either SAPT or DAPT using cilostazol and were followed for 0.5 to 3.5 years. The primary efficacy outcome was the first recurrence of ischemic stroke. The safety outcomes were severe or life-threatening bleeding.

Results

The DAPT group receiving cilostazol and either aspirin or clopidogrel and SAPT group receiving aspirin or clopidogrel alone comprised 464 (50.2%) and 461 (49.8%) patients, respectively. Ischemic stroke occurred in 12 of 464 patients (1.84 per 100 patient-years) in the DAPT group and 31 of 461 patients (4.42 per 100 patient-years) in the SAPT group, during follow-up. After adjusting for multiple potential confounding factors, ischemic stroke risk was significantly lower in the DAPT group than in the SAPT group (hazard ratio, 0.43 [95% CI, 0.22–0.84]). The rate of severe or life-threatening hemorrhage did not differ significantly between the groups (2 patients [0.31 per 100 patient-years] versus 6 patients [0.86 per 100 patient-years] in the DAPT and SAPT groups, respectively; hazard ratio, 0.36 [95% CI, 0.07–1.81]).

Conclusions

In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01995370. URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000012180.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stroke, LacunarStrokeMaleHumansAgedFemalePlatelet Aggregation InhibitorsCilostazolClopidogrelSecondary PreventionProspective StudiesDrug Therapy, CombinationAspirinHemorrhage

Stichwörter der Autor:innen

cilostazoldual anti-platelet therapyfollow-up studiesischemic strokelacunar strokesecondary prevention

Substanzen

Platelet Aggregation InhibitorsCilostazolClopidogrelAspirin

Autor:innen und Institutionen

  • Department of Neurology (Y.N., K.K.), Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Department of Hygiene and Public Health (T.O.), Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (K.T., T.Y.).
  • Clinical Research Center for Medicine, International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Medical Center, Tokyo, Japan (S.U.).
  • Department of Neurology, Tokyo Saiseikai Central Hospital, Japan (H.H.).
  • Department of Neurosurgery, Kobe City Medical Centre General Hospital, Japan (N.S.).

ORCID-Profile: Yasuhiro Nishiyama, Kazumi Kimura, Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Nobuyuki Sakai, Yasushi Okada, Hideki Origasa, Hiroaki Naritomi, Keiji Yamaguchi, Masayasu Matsumoto, Teiji Tominaga, Takenori Yamaguchi

Zitieren

APA

Nishiyama, Y., Kimura, K., Otsuka, T., Toyoda, K., Uchiyama, S., Hoshino, H., Sakai, N., Okada, Y., Origasa, H., Naritomi, H., Houkin, K., Yamaguchi, K., Minematsu, K., Matsumoto, M., Tominaga, T., Tomimoto, H., Terayama, Y., Yasuda, S., Yamaguchi, T., & CSPS.com Trial Investigators (2023). Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. Stroke, 54(3), 697-705. https://doi.org/10.1161/strokeaha.122.039900

Vancouver

Nishiyama Y, Kimura K, Otsuka T, Toyoda K, Uchiyama S, Hoshino H, et al. Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. Stroke. 2023;54(3):697-705. doi:10.1161/strokeaha.122.039900

BibTeX
@article{Nishiyama2023,
  author = {Nishiyama, Yasuhiro and Kimura, Kazumi and Otsuka, Toshiaki and Toyoda, Kazunori and Uchiyama, Shinichiro and Hoshino, Haruhiko and Sakai, Nobuyuki and Okada, Yasushi and Origasa, Hideki and Naritomi, Hiroaki and Houkin, Kiyohiro and Yamaguchi, Keiji and Minematsu, Kazuo and Matsumoto, Masayasu and Tominaga, Teiji and Tomimoto, Hidekazu and Terayama, Yasuo and Yasuda, Satoshi and Yamaguchi, Takenori and CSPS.com Trial Investigators, CSPS.com Trial Investigators},
  title = {Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial},
  journal = {Stroke},
  year = {2023},
  volume = {54},
  number = {3},
  pages = {697--705},
  doi = {10.1161/strokeaha.122.039900}
}
Kostenlos starten →